# A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects

> **NCT01668537** · PHASE2 · COMPLETED · sponsor: **Bavarian Nordic** · enrollment: 651 (actual)

## Conditions studied

- Smallpox

## Interventions

- **BIOLOGICAL:** LF formulation of IMVAMUNE®
- **BIOLOGICAL:** FD formulation of IMVAMUNE®

## Key facts

- **NCT ID:** NCT01668537
- **Lead sponsor:** Bavarian Nordic
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2014-01
- **Final completion:** 2014-06
- **Target enrollment:** 651 (ACTUAL)
- **Last updated:** 2020-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01668537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01668537, "A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT01668537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*